紅太陽(000525.SZ):擬2639萬元增資控股坤寧生物 共同合作開發百草枯解毒劑
格隆匯3月24日丨紅太陽(000525.SZ)公佈,為了共同合作開發百草枯特效解毒劑這一臨牀急救藥物,結束吡啶類除草劑近60年來無解藥的歷史,坤寧生物(“乙方”)同意引入公司(“甲方“)作為新股東增資乙方,甲方投資總金額暫定2639萬元;張鋼鈞、李國臨(“丙方”)同意放棄此次新增註冊資本的優先認購權。
增資完畢後,乙方註冊資本增加至3030萬元,其中甲方持有2030萬元註冊資本,佔67%;丙方持有註冊資本1000萬元,佔33%。新增投資將全部用於百草枯特效解毒劑的臨牀前研究和臨牀試驗。
坤寧生物經營範圍包括生物科技研發服務、技術開發;生物製藥技術及新藥、生物醫療技術、醫藥中間體(除化學危險品及易製毒化學品);貨物進出口(但國家限定經營或禁止進出口的商品和技術除外)。
截至2019年12月31日,坤寧生物總資產21.81萬元,總負債2.29萬元,淨資產19.52萬元,資產負債率為10.50%。2019年營業收入0元,營業利潤-6.25萬元,利潤總額-6.25萬元,歸屬於母公司淨利潤-6.25萬元。
公司表示,此次紅太陽增資控股坤寧生物的主要目的是通過整合雙方優勢,加快這一世界首創的百草枯特效解毒劑的開發及規模化、產業化生產,加速實現中國這一對世界人類生態文明重大科技成果的市場應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.